-
Patient-Relevant Benefits From Ixekizumab Treatment in Patients With Psoriasis: Data From the German National Psoriasis Registry PsoBest
Sep 9, 2025, 16:22 PM -
Understanding the Impact of the NICE Severity Modifier: A Targeted Review of Oncology Submissions
Sep 9, 2025, 16:22 PM -
Conceptualizing an Economic Model Structure for Parkinson's Disease
Sep 9, 2025, 16:22 PM -
Impact of Proteinuria and Declining Kidney Function on the Healthcare Resource Utilization and Associated Costs of Patients With IgA Nephropathy: A Retrospective Analysis in the UK and Spain
Sep 9, 2025, 16:22 PM -
Capturing the Realities of Hematological Cancer Patients’ Experiences of Novel Immunotherapies: A Call for Alignment and Action to Improve PROM Within CAR-T and Bispecific Antibody Therapies
Sep 9, 2025, 16:22 PM -
Clinical and Economic Characteristics of eGFR-Mutated NSCLC Patients Treated With TKIs in South Korea: A Retrospective Cross-Sectional Analysis
Sep 9, 2025, 16:22 PM -
Insights From a French Postmarketing Authorization Early Access (MA EA) Mechanism: Projecting Clinical and Economic Benefits of Neoadjuvant Nivolumab–Platinum-Based Chemotherapy (PDC) in Resectable Non-Small Cell Lung Cancer
Sep 9, 2025, 16:22 PM -
Elevating the Patient Perspective: Quantifying First-Line Preferences in Locally Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC) Using the Threshold Technique
Sep 9, 2025, 16:22 PM -
The Effects of Pooling Treatment Effects Targeting Treatment Policy and Hypothetical Estimands With Rank-Preserving Structural Failure Time Model in Oncology Aggregate-Level Meta-Analyses
Sep 9, 2025, 16:22 PM -
Evolution of National Price Negotiations for Pharmacy/Retail Medicines (Triparty Negotiations) in Sweden and Implications for Access
Sep 9, 2025, 16:22 PM -
Quantifying the Economic Burden of Osteoarthritis in Portugal: Insights From a Patient Journey Model
Sep 9, 2025, 16:22 PM -
Applying the Evidence-Generation Continuum Concept to Support Patient Access to Innovative Therapies in France: A Use Case in Rare Diseases
Sep 9, 2025, 16:22 PM -
Definitive Staging and Perioperative Treatment for Resectable Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC): A UK Perspective
Sep 9, 2025, 16:22 PM -
Do We Need to Measure Social Impact of Innovative Drugs?
Sep 9, 2025, 16:22 PM -
Effect of the Inflation Reduction Act on Drug Innovation
Sep 9, 2025, 16:22 PM -
Rescaled Tariff Regression for EQ-5D-5L Health State Valuation: An Equivalent Alternative to the Nonparametric Crosswalk
Sep 9, 2025, 16:22 PM -
Excel Front-End, R Back-End: A Gateway to Faster Individual Patient Simulations and Probabilistic Sensitivity Analyses in Cost-Effectiveness Models for HTA
Sep 9, 2025, 16:22 PM -
The Unique Value of Detecting Preeclampsia: Comparing Health Economic Analyses of Novel Diagnostics With the ISPOR Value Flower
Sep 9, 2025, 16:22 PM -
Clinically Informed, Cost-Sensitive Machine Learning for Predicting Hospital-Acquired Pressure Injuries: A Practical Approach Using Routinely Collected Data
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Intermittently Scanned Continuous Glucose Monitoring in Individuals With Type 2 Diabetes Using Insulin in Sweden: A National Real-World Evidence Perspective
Sep 9, 2025, 16:22 PM
